Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...

Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...

The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, according to a press release from the manufacturer. There are currently no ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to ...

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune ...

Are there key genes involved in TKI resistance in ccRCC? What mechanisms are associated with this development? A research team, led by Professor Ben Liu from the Department of Urology at the First ...